Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00530062 · ClinicalTrials.gov registry record · Phase 4
Comparison of Single-Dose Efficacy of an Albuterol Breath-Actuated Inhaler (Albuterol-HFA-BAI) Versus an Albuterol Metered-Dose Inhaler (Albuterol-HFA-MDI) in Participants With Asthma
A Phase 4 study of Asthma, sponsored by Teva Branded Pharmaceutical Products R&D.
- Completed
- Registry status
- Phase 4
- Development phase
- 49
- Enrollment target
- 5
- Study locations
NCT00530062 is a Phase 4 study of Asthma that has completed, run by Teva Branded Pharmaceutical Products R&D. The registered enrollment target is 49 participants, below the 1,563-participant average among 374 other Asthma trials with a reported enrollment target (97% lower). The trial reports 5 study locations across 5 states.
The verdict
NCT00530062, a Phase 4 study of Asthma, has completed, sponsored by Teva Branded Pharmaceutical Products R&D.
- COMPLETED
- Registry status
- Phase 4
- Development phase
- 49 participants
- Enrollment target
- 5
- Study locations
Study Summary
This is a research study designed to compare the single-dose efficacy of albuterol-hydrofluoroalkane-breath-actuated inhaler (HFA-BAI) and albuterol-HFA-metered-dose inhaler (MDI) in asthmatics with poor inhaler coordinating abilities.
Conditions Studied
Interventions
- DRUG Albuterol-HFA-MDI
- DRUG Albuterol-HFA-BAI
Study Locations (5)
California
- Clinical Study Site - Huntington Beach
Colorado
- Teva Clinical Study Site - Lakewood
Minnesota
- Clinical Study Site - Minneapolis
Oklahoma
- Clinical Study Site - Oklahoma City
Oregon
- Clinical Study Site - Lake Oswego
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 49 participants |
| Start Date | 2007-07-25 |
| Est. Completion | 2008-10-24 |
| Phase | Phase 4 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00530062
The ClinicalTrials.gov registry entry for NCT00530062 describes a study currently listed as completed, categorized as Phase 4. The registered enrollment target is 49 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 1,563-participant average among 374 other Asthma trials with a reported enrollment target (97% lower). The listed sponsor is Teva Branded Pharmaceutical Products R&D, which has 167 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Asthma appearing as the primary indexed condition, and to 2 interventions - of which Albuterol-HFA-MDI is the first listed.
NCT00530062 reports 5 study locations spanning 5 distinct geographic areas - top geographies include California, Colorado, Minnesota.
Frequently Asked Questions
What is clinical trial NCT00530062 about?
NCT00530062 is a clinical study titled "Comparison of Single-Dose Efficacy of an Albuterol Breath-Actuated Inhaler (Albuterol-HFA-BAI) Versus an Albuterol Metered-Dose Inhaler (Albuterol-HFA-MDI) in Participants With Asthma". This is a research study designed to compare the single-dose efficacy of albuterol-hydrofluoroalkane-breath-actuated inhaler (HFA-BAI) and albuterol-HFA-metered-dose inhaler (MDI) in asthmatics with poor inhaler coordinating abilities.
What is the current status of trial NCT00530062?
This trial is currently completed. It is a Phase 4 study. The enrollment target is 49 participants. The study started on 2007-07-25. Estimated completion is 2008-10-24.
What conditions does trial NCT00530062 study?
This clinical trial studies the following conditions: Asthma.
What interventions are being tested in trial NCT00530062?
The interventions under investigation include: Albuterol-HFA-MDI (DRUG), Albuterol-HFA-BAI (DRUG).
Who is sponsoring clinical trial NCT00530062?
This trial is sponsored by Teva Branded Pharmaceutical Products R&D, which has 167 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT00530062 being conducted?
This trial has 5 study locations across California, Colorado, Minnesota, Oklahoma, Oregon. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Asthma
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Measuring the Effect of Dupilumab Treatment on Mucociliary Clearance (MCC) in Subjects With Moderate to Severe Asthma
RECRUITING · Phase 4
-
Study Assessing the Long-term Effect of Dupilumab on Prevention of Lung Function Decline in Adult Patients With Uncontrolled Moderate to Severe Asthma
RECRUITING · Phase 4
-
Viral Infection in Asthma (VIA) Study
RECRUITING · Phase 4
-
Mechanism(s) of Airflow Limitation During Exacerbation of Asthma
RECRUITING · Phase 4
-
The Effects of Positive Airway Pressure on the Mucolytic Effects of NAC (TEAM)
RECRUITING · Phase 4
-
Efficacy of Dupilumab Added to Medium Dose Inhaled Corticosteroid/Long-acting Beta-agonist (ICS/LABA) in Comparison to ICS Dose Escalation to High Dose ICS/LABA in Adolescent and Adult Patients With Uncontrolled Asthma
RECRUITING · Phase 4
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.